Evolving Strategies for Target Selection for Antibody-Drug Conjugates

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Antibody-drug conjugates (ADCs) are an advanced cancer treatment strategy.
• ADCs deliver potent cytotoxic drugs specifically to tumor cells via antibody-antigen recognition.
• Effective target selection is critical for maximizing ADC therapeutic windows and efficacy.

Purpose of the Study:

• To analyze tumor and normal tissue expression profiles of current ADC targets.
• To identify optimal parameters for ADC target selection.
• To discuss factors influencing ADC target selection and clinical development strategies.

Main Methods:

• Surveyed expression profiles of ADC targets in tumor and normal tissues.
• Analyzed interdependencies between drug properties, target biology, and clinical strategies.
• Utilized TPBG (5T4) antigen and A1-mcMMAF ADC as a case study.

Main Results:

• ADC target expression profiles are highly diverse.
• No universal optimal parameters for ADC target selection were identified.
• Target biological function significantly impacts ADC efficacy, as shown with TPBG (5T4).

Conclusions:

• ADC target selection is complex and requires multifaceted considerations beyond simple expression levels.
• Emerging technologies and biological insights are expanding the scope of ADC target discovery.
• A comprehensive approach integrating target biology, drug properties, and clinical strategy is essential for successful ADC development.